Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2021. Mr. Kåre Schultz, Teva's President and CEO, said, “We have performed well in the second quarter, improving our profitability and free cash flow generation. This allowed us to reduce our net debt by an additional $500 million to $22.7 billion, once again demonstrating our commitment to and confidence in our long-term goals. Among our growth driv

Teva Reports Second Quarter 2021 Financial Results

Root

Some of the market's best bargains have single-digit share prices.

The Smartest Stocks Under $10 to Buy Right Now

We believe that Teva Pharmaceutical stock is a good buying opportunity at the present time. TEVA stock trades near $10 currently and it is, in fact, down 28% from its pre-Covid high of around $13 in Feb 2020 – before the coronavirus pandemic hit the world.

Will Teva Stock Rebound After A 10% Fall In A Month?

Chevron

Globe Life Inc

Procter & Gamble

Verizon

As of March 31, Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK-B) had 48 stocks in its portfolio.

Warren Buffett's 6 Worst-Performing Stocks in Q2

Teva stock abruptly fell below $10 last week. Markets ignore two key product drivers for free cash flow growth.

What To Do After Teva Stock Falls Below $10 Again

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is recalling one lot of its cancer drug topotecan injection after a pharmacy complaint flagged the presence of a single glass particulate in a vial of the drug.  A follow-up review of the suspect sample turned up two other particles, which have been identified as grey silicone and “translucent, colorless cotton fiber,” a notice on the FDA's website said.

Teva Recalls One Batch Of Topotecan After Complaint Of Glass Particulate In Vial

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 928

Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021

AbbVie

AmerisourceBergen

Cardinal Health

CVS Health

Endo International

Johnson & Johnson

McKesson

Rite Aid

Walgreens

Walmart

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors, urging them to hold the companies liable. Jayne Conroy, representing Suffolk County, also said that the drug distributors - AmerisourceBergen Corp (NYSE: ABC), Cardinal Health Inc (NYSE: CAH), and McKesson Corp (NYSE: MCK) failed to report suspicious opioid orders as required.

New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid

TEL AVIV, Israel & ZURICH--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG ("Bioeq") today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq's FYB201, a biosimilar candidate to Lucentis® (ranibizumab) in Europe, Canada, Israel and New Zealand. This strategic partnership combines Teva's long-standing commercial presence, extensive distribution network and wide-reaching sales and marketing activities

Teva and Bioeq Announce Commercial Partnership for Biosimilar

Amazon

Bank of America

Bristol-Myers

Mastercard

These growth and value stocks are begging to be bought by investors.

5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021

TEL AVIV--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan. “In Japan, the annual prevalence of migraine is 8.4% of adults1 and now, together with our partner, Teva is able to offer people living with migraine in Japan this biopharmaceutical treatment with flexible dosing options to help man

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its U.S. launch of the first generic version of twice daily PERFOROMIST®, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. “Teva is pleased to provide patients with first-to-mar

Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States

AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patie

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea. With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, 1 in 11 generic prescriptions dispensed in the U.S. i

Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea

Teva Pharmaceutical Industries Ltd. (TEVA) was a big mover last session on higher-than-average trading volume.

Teva Pharmaceutical Industries Ltd. (TEVA) Moves 7.5% Higher: Will This Strength Last?

The Oracle of Omaha has a knack for owning great companies that can make investors rich.

3 Buffett Stocks to Buy Hand Over Fist in June

TORONTO--(BUSINESS WIRE)--Teva Canada's Life Effects website features real-life stories from patients and caregivers about the reality of living with chronic conditions.

Teva Canada Provides New Patient Resource to Empower Those Living with Chronic Conditions

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that 11 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection will be presented at the 2021 American Headache Society (AHS) Annual Meeting, taking place virtually June 3-6. “Our goal is to continue supporting the migraine community through our rigorous and innovative scientific

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva's Longstanding Heritage in the Management of Migraine

Without legal risks, Teva would be a compelling long, with ~200% upside potential if the company can meet 2023 targets, which I think is possible. However, legal risks, particularly the lack of a nationwide opioid settlement, exacerbate refinancing risks in 2023, making bankruptcy a material possibility.

Teva: $30 Or $0 - Legal Risks Offer Setup For A Strangle Or Straddle

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets

TEL AVIV, Israel and PARSIPPANY, N.J., May 17, 2021 /PRNewswire/ -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets

Merck

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Even the Oracle of Omaha is staring at some unrealized losses in his investment portfolio.

3 Stocks Warren Buffett Is Losing Money On Right Now

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it will present two new e-posters at the upcoming American Thoracic Society (ATS) International Conference, taking place virtually May 14-19, 2021. One of the two e-posters details data on increased short-acting beta-agonist (SABA) use in patients with poorly controlled asthma, as measured by Teva's ProAir® Digihaler® (al

Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference

Francisco Garcia Parames (Trades, Portfolio), founder and leader of Spanish investment firm Cobas Asset Management, disclosed his first-quarter portfolio earlier this week.

The Top 5 Trades of Francisco Garcia Parames' Firm

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company's efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency. The report highlights new ambitious goals, including launching eight programs to increase access to medicines globally by 2025 and reducing Scope 1 and 2 greenhouse gas

News for Teva Pharmaceutical Stock (TEVA)